161 related articles for article (PubMed ID: 16088366)
61. Willingness to participate in South African HIV vaccine trials--concerns of medical professionals in the Western Cape.
Moodley K; Barnes J; van Rensburg EJ; Myer L
S Afr Med J; 2002 Nov; 92(11):904-6. PubMed ID: 12506594
[TBL] [Abstract][Full Text] [Related]
62. Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs.
Park JN; White B; Bates A; Enriquez J; Liao L; Maher L
Drug Alcohol Depend; 2012 Jun; 123(1-3):35-40. PubMed ID: 22071117
[TBL] [Abstract][Full Text] [Related]
63. An assessment of fishing communities around Lake Victoria, Uganda, as potential populations for future HIV vaccine efficacy studies: an observational cohort study.
Kiwanuka N; Mpendo J; Nalutaaya A; Wambuzi M; Nanvubya A; Kitandwe PK; Muyanja E; Ssempiira J; Balyegisawa A; Ssetaala A;
BMC Public Health; 2014 Sep; 14():986. PubMed ID: 25242015
[TBL] [Abstract][Full Text] [Related]
64. Socioeconomic status and HIV vaccine preparedness studies in North America.
Dhalla S; Poole G
Vaccine; 2015 May; 33(22):2536-45. PubMed ID: 25820065
[TBL] [Abstract][Full Text] [Related]
65. Young at risk-people in Maputo City, Mozambique, present a high willingness to participate in HIV trials: Results from an HIV vaccine preparedness cohort study.
Capitine IPU; Macicame IB; Uanela AM; Bhatt NB; Yates A; Milazzo M; Nwoga C; Crowell TA; Michael NL; Robb ML; Jani IV; Kroidl A; Polyak CS; De Schacht C;
PLoS One; 2021; 16(12):e0260126. PubMed ID: 34855790
[TBL] [Abstract][Full Text] [Related]
66. Who will enroll? Predicting participation in a phase II AIDS vaccine trial.
Halpern SD; Metzger DS; Berlin JA; Ubel PA
J Acquir Immune Defic Syndr; 2001 Jul; 27(3):281-8. PubMed ID: 11464149
[TBL] [Abstract][Full Text] [Related]
67. Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand.
MacQueen KM; Vanichseni S; Kitayaporn D; Lin LS; Buavirat A; Naiwatanakul T; Raktham S; Mock P; Heyward WL; Des Jarlais DC; Choopanya K; Mastro TD
J Acquir Immune Defic Syndr; 1999 Jul; 21(3):243-51. PubMed ID: 10421249
[TBL] [Abstract][Full Text] [Related]
68. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies.
Temoshok LR
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S277-80. PubMed ID: 7865318
[No Abstract] [Full Text] [Related]
69. Willingness to Participate in Hypothetical HIV Vaccine Trial and Associated Factors among People Who Inject Drugs in Dar es Salaam, Tanzania.
Iseselo MK; Tarimo EAM; Sandstrom E; Kulane A
Biomed Res Int; 2020; 2020():8507981. PubMed ID: 32714988
[TBL] [Abstract][Full Text] [Related]
70. Inhibitors and facilitators of willingness to participate (WTP) in an HIV vaccine trial: construction and initial validation of the Inhibitors and Facilitators of Willingness to Participate Scale (WPS) among women at risk for HIV infection.
Fincham D; Kagee A; Swartz L
AIDS Care; 2010 Apr; 22(4):452-61. PubMed ID: 20146113
[TBL] [Abstract][Full Text] [Related]
71. More women and adolescents needed in HIV vaccine trials.
Expert Rev Vaccines; 2004 Oct; 3(5):501-7. PubMed ID: 15485328
[No Abstract] [Full Text] [Related]
72. A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users.
Seal KH; Kral AH; Lorvick J; McNees A; Gee L; Edlin BR
Drug Alcohol Depend; 2003 Aug; 71(2):127-31. PubMed ID: 12927650
[TBL] [Abstract][Full Text] [Related]
73. Required HIV antibody testing, social risk, and HIV-vaccine efficacy trials.
MacQueen KM; Buchbinder SP; Douglas JM; Judson FN; McKirnan DJ; Bartholow BN
AIDS Public Policy J; 1996; 11(2):104-12. PubMed ID: 10915243
[No Abstract] [Full Text] [Related]
74. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team.
Koblin BA; Holte S; Lenderking B; Heagerty P
J Acquir Immune Defic Syndr; 2000 Aug; 24(5):451-7. PubMed ID: 11035616
[TBL] [Abstract][Full Text] [Related]
75. Unique risks to volunteers in HIV vaccine trials.
Frey SE
J Investig Med; 2003 Feb; 51 Suppl 1():S18-20. PubMed ID: 12664950
[TBL] [Abstract][Full Text] [Related]
76. Vaccine study is enrolling.
AIDS Patient Care STDS; 2005 Apr; 19(4):276-7. PubMed ID: 15920787
[No Abstract] [Full Text] [Related]
77. An update on human immunodeficiency virus vaccine preparedness studies.
Dhalla S
J Med Microbiol; 2015 Jul; 64(7):731-738. PubMed ID: 25908608
[TBL] [Abstract][Full Text] [Related]
78. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials.
Hays RB; Kegeles SM
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Feb; 20(2):164-71. PubMed ID: 10048904
[TBL] [Abstract][Full Text] [Related]
79. Willingness to participate in HIV vaccine trials: the impact of trial attributes.
Newman PA; Duan N; Lee SJ; Rudy E; Seiden D; Kakinami L; Cunningham W
Prev Med; 2007 Jun; 44(6):554-7. PubMed ID: 17275895
[TBL] [Abstract][Full Text] [Related]
80. Response to Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial.
Halpern SD
J Acquir Immune Defic Syndr; 2003 Jul; 33(3):412. PubMed ID: 12843757
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
